Drug Discovery Science and Technology, AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064-6101, USA.
Chem Commun (Camb). 2019 Aug 1;55(63):9241-9250. doi: 10.1039/c9cc02824b.
The field of chemical biology has introduced several approaches, typically using chemical probes, to measure the direct binding interaction of a small molecule with its biological target in cells. The use of these direct target engagement assays in pharmaceutical development can support mechanism of action hypothesis testing, rank ordering of compounds, and iterative improvements of chemical matter. This Feature Article highlights a newer application of these approaches: the quantification of target engagement in animal models to support late stage preclinical development and the nomination of a drug candidate to clinical trials. Broadly speaking, these efforts can be divided between compounds that covalently and reversibly interact with protein targets; recent examples for both categories are discussed for a range of targets, along with their limitations. New, promising technologies are also highlighted, in addition to the application of target engagement determination to new therapeutic modalities.
化学生物学领域已经引入了几种方法,通常使用化学探针,来测量小分子在细胞中与其生物靶标的直接结合相互作用。在药物开发中使用这些直接靶标结合测定法可以支持作用机制假说测试、化合物的排序以及化学物质的迭代改进。本文重点介绍了这些方法的一个新应用:在动物模型中定量靶标结合,以支持后期临床前开发,并提名候选药物进行临床试验。广义而言,这些努力可以分为与蛋白质靶标共价和可逆相互作用的化合物;讨论了这两类化合物的最新实例,涵盖了一系列靶标及其局限性。除了将靶标结合测定应用于新的治疗模式外,还突出了新的有前途的技术。